CARGO Therapeutics has established a differentiated manufacturing process to support its ongoing CD22 CAR clinical program. Our highly experienced Technical Operations team is leveraging the industry learnings from the first generation CAR Ts to develop efficient and cost-effective approaches for autologous CAR T-cell therapy. Our team is focused on addressing key challenges of access, cost and supply reliability associated with autologous cell therapy manufacturing. Through a combination of flexible, automated process design, next generation rapid analytics and viral vector production technologies, we can make transformational progress towards increased patient access to autologous CAR T therapies. Our overarching goal is to ensure supply for clinical development and ultimately commercialization while maintaining product comparability through product life cycle.
Chemistry, Manufacturing and Controls (CMC)
CARGO’s CMC approach focuses on addressing key challenges of access, cost and supply reliability associated with autologous cell therapy manufacturing. CARGO has assembled a strong team of technical experts who are leveraging their past experiences to accelerate development of autologous CAR Ts.